Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ).
Hemogenyx Pharmaceuticals announced its total issued share capital consists of 4,343,539 ordinary shares, with no shares held in treasury. This figure is crucial for shareholders to determine their investment status under the Financial Conduct Authority’s rules, impacting how they manage their interests in the company’s share capital.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing several product candidates and platform technologies.
Average Trading Volume: 40,789
Technical Sentiment Signal: Sell
Current Market Cap: £7.71M
Learn more about HEMO stock on TipRanks’ Stock Analysis page.